Tag: Immunology & Inflammation
PharmaSignal — Immunology & Inflammation therapeutic area
Lilly exits Rigel alliance, adding to RIPK1 scrap heap
BioSpace
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous sys
BioAegis and Prenosis partner for inflammatory disease therapies
Pharmaceutical Business Review
The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without
BioAegis and Prenosis partner for inflammatory disease therapies
Pharmaceutical Technology
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug
BioPharma Dive
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting NLRP3, an inflammasome linked to a variety of health conditions.
FDA kicks off review of Roche’s Gazyva for wider lupus use
Pharmaphorum
Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.
Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers
BioPharma Dive
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.
BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut
BioSpace
Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
BioPharma Dive
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street s expectations and surpass $15 billion in first-quarter drug sales.
Spyre drug for inflammatory bowel disease shows promise in early study
BioPharma Dive
The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
BioSpace
Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie’s deal with the White House to avoid tariffs.
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
BioSpace
Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”
Sanofi immune drug hopeful posts mixed results in mid-stage tests
BioPharma Dive
Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.
FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries
BioSpace
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile.
FDA points to liver injury with Amgen’s Tavneos
Pharmaphorum
The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.
Biogen, with $5.6B Apellis buy, builds out immunology offerings
BioPharma Dive
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline
BioSpace
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunol
Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents
Big Molecule Watch
On March 20, 2026, Accord BioPharma, Inc.
Novartis targets Xolair successor in buyout of startup Excellergy
BioPharma Dive
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche s popular medicine.
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
BioPharma Dive
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.
Apogee strengthens case for longer-lasting eczema drug
BioPharma Dive
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.